DESTINY-Breast04

NCT03734029 📎

Regimen

Experimental
Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks.
Control
Treatment of physician's choice chemotherapy (capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel).

Population

HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer, predominantly HR-positive (~88%), previously treated with 1-2 lines of chemotherapy for metastatic disease.

Key finding

DESTINY-Breast04 created a new actionable breast cancer subtype: HER2-low. FDA approved T-DXd for HER2-low MBC Aug 2022. NCCN category 1; first biologically targeted therapy for what was previously considered HER2-negative disease.

Source: PMID 35665782

Timeline

  • Publication: 2022 Jul 7

Guideline citations

  • NCCN BREAST